» Articles » PMID: 35922729

Effects of Progesterone on Preclinical Animal Models of Traumatic Brain Injury: Systematic Review and Meta-analysis

Overview
Journal Mol Neurobiol
Date 2022 Aug 3
PMID 35922729
Authors
Affiliations
Soon will be listed here.
Abstract

Since the publication of two phase III clinical trials not supporting the use of progesterone in patients with traumatic brain injury (TBI), several possible explanations have been postulated, including limitations in the analysis of results from preclinical evidence. Therefore, to address this question, a systematic review and meta-analysis was performed to evaluate the effects of progesterone as a neuroprotective agent in preclinical animal models of TBI. A total of 48 studies were included for review: 29 evaluated brain edema, 21 evaluated lesion size, and 0 studies reported the survival rate. In the meta-analysis, it was found that progesterone reduced brain edema (effect size - 1.73 [- 2.02, - 1.44], p < 0.0001) and lesion volume (effect size - 0.40 [- 0.65, - 0.14], p = 0.002). Lack of details in the studies hindered the assessment of risk of bias (through the SYRCLE tool). A funnel plot asymmetry was detected, suggesting a possible publication bias. In conclusion, preclinical studies show that progesterone has an anti-edema effect in animal models of TBI, decreasing lesion volume or increasing remaining tissue. However, more studies are needed using assessing methods with lower risk of histological artifacts.

Citing Articles

Progesterone and Estradiol Levels Associated with Concussion and Clinical Outcomes and Recovery in Female Athletes and Cadets.

Goeckner B, Huber D, VAN Bortel K, Gill J, Mannix R, Master C Med Sci Sports Exerc. 2024; 57(3):524-534.

PMID: 39501473 PMC: 11828682. DOI: 10.1249/MSS.0000000000003591.


Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma.

Chen H, Lin H, Chiang Y, Yang W, Wang C, Yang P J Exp Clin Cancer Res. 2024; 43(1):218.

PMID: 39103871 PMC: 11302026. DOI: 10.1186/s13046-024-03144-2.


Neuroprotective and neuroregenerative drugs after severe traumatic brain injury : A narrative review from a clinical perspective.

Grgac I, Herzer G, Voelckel W, Secades J, Trimmel H Wien Klin Wochenschr. 2024; 136(23-24):662-673.

PMID: 38748062 DOI: 10.1007/s00508-024-02367-9.


Research progress on pleiotropic neuroprotective drugs for traumatic brain injury.

Zhao Q, Li H, Li H, Zhang J Front Pharmacol. 2023; 14:1185533.

PMID: 37475717 PMC: 10354289. DOI: 10.3389/fphar.2023.1185533.

References
1.
Boto G, Gomez P, DE LA Cruz J, Lobato R . A historical analysis of severe head injury. Neurosurg Rev. 2008; 32(3):343-53. DOI: 10.1007/s10143-008-0178-9. View

2.
Harvey L, Close J . Traumatic brain injury in older adults: characteristics, causes and consequences. Injury. 2012; 43(11):1821-6. DOI: 10.1016/j.injury.2012.07.188. View

3.
Asemota A, George B, Bowman S, Haider A, Schneider E . Causes and trends in traumatic brain injury for United States adolescents. J Neurotrauma. 2012; 30(2):67-75. DOI: 10.1089/neu.2012.2605. View

4.
Wright D, Bauer M, Hoffman S, Stein D . Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. J Neurotrauma. 2001; 18(9):901-9. DOI: 10.1089/089771501750451820. View

5.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E . Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(10):718-79. DOI: 10.1016/j.euroneuro.2011.08.008. View